 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H23NO |
| Molar mass | 245.366 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Methyl-alpha-PVP (3-Me-PVP, O-2480) is a substituted cathinone derivative with stimulant effects, [1] which has been sold as a designer drug. It was first identified in Sweden in June 2023. [2]
Pyrovalerone is a central nervous system (CNS) stimulant that acts as a norepinephrine–dopamine reuptake inhibitor (NDRI). It was developed in the 1980s and had briefly been approved in Spain and France for chronic fatigue or lethargy and as an appetite suppressant, but was withdrawn from both markets around 2001 due to safety concerns including problems with abuse and dependence. It is closely related on a structural level to a number of other cathinone stimulants, such as α-PVP, MDPV and prolintane.
α-Pyrrolidinopropiophenone (α-PPP), is a stimulant drug. It is similar in structure to the appetite suppressant diethylpropion and has analogous effects in animals. Little is known about this compound, but it has been detected by laboratories in Germany as an ingredient in "ecstasy" tablets seized by law enforcement authorities. This drug has been found to produce stimulant effects in animals and produces highly stimulating effects in humans, based on the experiences of the individuals who have tried it. Most of the individuals who have tried it prefer α-PVP to it, but prefer this drug over α-PVT. It is said to lack euphoria compared to α-PVP.
Prolintane is a central nervous system (CNS) stimulant and norepinephrine–dopamine reuptake inhibitor (NDRI) developed in the 1950s. Being an amphetamine derivative, it is closely related in chemical structure to other drugs such as pyrovalerone, MDPV, and propylhexedrine, and has a similar mechanism of action. Many cases of prolintane abuse have been reported.
α-Pyrrolidinopentiophenone (α-PVP), also known as α-pyrrolidinovalerophenone, O-2387, β-keto-prolintane, prolintanone, or desmethylpyrovalerone, is a synthetic stimulant of the cathinone class developed in the 1960s that has been sold as a designer drug and often consumed for recreational reasons. α-PVP is chemically related to pyrovalerone and is the ketone analog of prolintane.
Naphyrone, also known as O-2482 and naphthylpyrovalerone, is a substituted cathinone drug derived from pyrovalerone that acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), producing stimulant effects and has been reported as a novel designer drug. No safety or toxicity data is available on the drug.
4'-Methyl-α-pyrrolidinohexiophenone (MPHP) is a stimulant compound which has been reported as a novel designer drug. It is closely related to pyrovalerone, being simply its chain-lengthened homologue. In the pyrrolidinophenone series, stimulant activity is maintained so long as the positions of the aryl, ketone and pyrrolidinyl groups are held constant, while the alkyl backbone can be varied anywhere between three and as many as seven carbons, with highest potency usually seen with the pentyl or isohexyl backbone, and a variety of substituents are tolerated on the aromatic ring.
1-(2-Phenylethyl)pyrrolidine (PEP) is a chemical compound. It is an analogue of 2-phenylethylamine where the amine has been replaced by a pyrrolidine ring. The β-keto derivative is phenacylpyrrolidine and the α-methyl and β-keto derivative is α-pyrrolidinopropiophenone (α-PPP).
4-Ethylmethcathinone (4-EMC) is a recreational designer drug of the stimulant and entactogen class. It is a structural isomer of 4-MEC and 3,4-DMMC. It has been identified in many countries around the world, initially in Europe but was first found in Australia in 2020.
α-Pyrrolidinohexiophenone is a synthetic stimulant drug of the cathinone class developed in the 1960s which has been reported as a novel designer drug.
α-Pyrro
4'-Methoxy-α-pyrrolidinopentiophenone is a stimulant drug of the cathinone class that has been sold online as a designer drug.
3',4'-Dimethoxy-α-pyrrolidinopentiophenone is a synthetic stimulant drug of the cathinone class that has been sold online as a designer drug. It is a relatively weak inhibitor of serotonin reuptake and has little affinity in vitro for dopamine or noradrenaline transporters.
4'-Fluoro-α-pyrrolidinopentiophenone is a stimulant drug of the cathinone class which has been reported as a novel designer drug.
Indapyrophenidone is a synthetic drug of the cathinone class that has been sold online as a designer drug.
4-Chloro-α-pyrrolidinovalerophenone is an emerging recreational designer drug of the pyrrolidinophenone class, similar in structure to α-pyrrolidinopentiophenone (α-PVP). The pharmacology and toxicity of this compound is unknown, though it is presumed to be a stimulant drug.
α-Pyrrolidinoisohexanophenone is a stimulant drug of the cathinone class that has been sold online as a designer drug. It acts as a potent norepinephrine-dopamine reuptake inhibitor (NDRI). In July 2016 α-PiHP was first identified as a designer drug when it was reported to the EMCDDA by a forensic laboratory in Slovenia. It is a positional isomer of pyrovalerone, with the methyl group shifted from the 4-position of the aromatic ring to the 4-position of the acyl chain. Similarly to other cathinones, use of α-PiHP can result in compulsive redosing, addiction, anxiety, paranoia, and psychosis.
4-Ethyl-alpha-Pyrrolidinovalerophenone (4-Et-PVP) is a recreational designer drug from the substituted cathinone family, with stimulant effects. It was first identified in Hungary in March 2019.
O-2390 is a recreational designer drug from the substituted cathinone family, which acts as a potent inhibitor of dopamine and noradrenaline reuptake in vitro, with weaker but still significant inhibition of serotonin reuptake.
MFPVP (3-Methyl-4-fluoro-α-pyrrolidinovalerophenone) is a recreational designer drug from the substituted cathinone family, with stimulant effects. It was first identified in Sweden in April 2020 and was among the most widely encountered substituted cathinone derivatives in 2021, though it since appears to have declined in prevalence. It is illegal in Virginia.